SecBot SecBot
8-K ·Filed May 14, 2026

KPTI

Karyopharm Therapeutics Inc.
MIXED
Impact 6/10
Horizonweeks Processed6mo ago SEC0001193125-26-222808
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The EPS beat and reaffirmed guidance are positive, but the massive $400M shelf (200% of market cap) and going-concern warning dominate the risk profile. The SENTRY trial's mixed results (met spleen endpoint, missed symptom endpoint) create binary ASCO catalyst risk on June 2. The cash runway into late Q3 2026 forces a near-term capital raise, likely highly dilutive. Traders should watch for the ASCO presentation on June 2 and any pre-announcement of financing terms.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$8.90
T+0 close · May 14, 2026 · via day close
Latest settled
+6.74%
T+20 · $9.50
Vs SPY
+7.60%
α at T+20
Next horizon
T+60
due 3mo ago
  1. T+0 · May 14 $8.90entry
  2. T+1 · 6mo ago −13.82%α −12.59% · $7.67
  3. T+5 · 6mo ago −9.44%α −8.72% · $8.06
  4. T+20 · 5mo ago +6.74%α +7.60% · $9.50
  5. T+60 · due 3mo ago Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Karyopharm reported Q1 2026 total revenue of $35.1M (up 17% YoY) and a net loss of $22.4M ($1.02 per basic share), beating consensus EPS of -$1.44 by 29%. The company reaffirmed full-year 2026 revenue guidance of $130M-$150M and completed enrollment in the Phase 3 XPORT-EC-042 endometrial cancer trial. However, the Phase 3 SENTRY myelofibrosis trial missed its second co-primary endpoint (symptom score), and a $400M shelf registration filed 10 days ago (including a $100M ATM) represents massive potential dilution (~200% of market cap) with a going-concern warning. The cash runway extends only into late Q3 2026, creating acute financing risk.

Key Financial Metrics

EPS
−$1.02
est −$1.44 · +29.2%
Revenue
$35.1M
est $31.4M · +11.7% · +16.8% YoY
Rating
in line
Guidance
$130M-$150M
maintained

Key Facts

  • Q1 2026 total revenue $35.1M vs $30.0M YoY (+17%); net product revenue $29.2M vs $21.1M YoY (+38%)
  • Net loss $22.4M ($1.02 basic share) vs consensus EPS -$1.44, a 29% beat
  • Full-year 2026 guidance reaffirmed: total revenue $130M-$150M, XPOVIO net product revenue $115M-$130M
  • Phase 3 SENTRY myelofibrosis trial met SVR35 endpoint but missed Abs-TSS symptom score co-primary endpoint
  • Phase 3 XPORT-EC-042 endometrial cancer trial enrollment completed (n=257); topline data expected mid-2026
  • Cash $91.2M as of March 31, 2026, including ~$50M from Q1 2026 financing; runway only into late Q3 2026
  • $400M universal shelf registration (including $100M ATM) filed May 4, 2026, ~200% of market cap
  • Auditor raised substantial doubt about going concern; massive potential dilution ahead

Financial Impact

Q1 2026 revenue $35.1M (+17% YoY); net loss $22.4M improved from $23.5M YoY; cash burn ~$9M/month; $400M shelf overhang

revenuenet losscash runwaydilution

Risk Factors

  • Massive dilution from $400M shelf registration (~200% of market cap), likely near-term capital raise
  • Going-concern warning with cash runway only into late Q3 2026
  • SENTRY trial missed symptom endpoint, ASCO presentation on June 2 could disappoint
  • XPOVIO demand declining due to new competitive entrants in multiple myeloma
  • High debt load ($224M in convertible notes + $120M secured term loan + $72M deferred royalty)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-222808
Document: kpti-20260514.htm0001193125-26-222808
Document: 0001193125-26-222808-index-headers.html0001193125-26-222808
Document: 0001193125-26-222808-index.html0001193125-26-222808
Document: 0001193125-26-222808.txt0001193125-26-222808
8-K Data (Synthetic)0001193125-26-222808

US Market Status

Market Closed · Opens in 7h 46m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026